Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU,China,Nov. 28,2024-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical company that develops,manufactures and commercializes high qu